{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:41Z","timestamp":1793931701181,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273350"],"award-info":[{"award-number":["82273350"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Central Government's Guidance Fund for Local Science and Technology Development","award":["236Z7710G"],"award-info":[{"award-number":["236Z7710G"]}]},{"name":"Wuxi Taihu Talents Program Medical and Health High-level Talents Project"},{"name":"National High Level Hospital Clinical Research Funding","award":["2024IR30"],"award-info":[{"award-number":["2024IR30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-06003-y","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:14:49Z","timestamp":1735622089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["YWHAG promotes bladder cancer metastasis by regulating TMOD3 to activate ERK1\/2 and JNK phosphorylation in the MAPK pathway"],"prefix":"10.1186","volume":"22","author":[{"given":"Tai","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"1","key":"6003_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Prim. 2023;9(1):58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9.","journal-title":"Nat Rev Dis Prim"},{"issue":"19","key":"6003_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"JAMA"},{"issue":"1","key":"6003_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"5","key":"6003_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323. https:\/\/doi.org\/10.3322\/caac.21631.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6003_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"issue":"4","key":"6003_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, Turturica D, Bauerov\u00e1 L, Bruins HM, et al. European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033.","journal-title":"Eur Urol"},{"issue":"3","key":"6003_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017;198(3):552\u20139. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086.","journal-title":"J Urol"},{"issue":"5","key":"6003_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"JWF Catto","year":"2021","unstructured":"Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S, et al. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol. 2021;79(5):621\u201332. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.032.","journal-title":"Eur Urol"},{"issue":"5","key":"6003_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2021.04.012","volume":"39","author":"M Knowles","year":"2021","unstructured":"Knowles M, Dyrskj\u00f8t L, Heath EI, Bellmunt J, Siefker-Radtke AO. Metastatic urothelial carcinoma. Cancer Cell. 2021;39(5):583\u20135. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.012.","journal-title":"Cancer Cell"},{"key":"6003_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384: e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743.","journal-title":"BMJ"},{"key":"6003_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68: 100938. https:\/\/doi.org\/10.1016\/j.drup.2023.100938.","journal-title":"Drug Resist Updat"},{"issue":"10364","key":"6003_CR12","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/s0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(22)01188-6.","journal-title":"Lancet"},{"issue":"10","key":"6003_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"11","key":"6003_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol"},{"issue":"21","key":"6003_CR15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"issue":"6_Supplement","key":"6003_CR16","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1158\/1538-7445.Am2024-4632","volume":"84","author":"J Luo","year":"2024","unstructured":"Luo J, Gao SP, Kuo F, Ozcan GG, Basar M, Koll F, et al. Abstract 4632: Lineage plasticity as a determinant of antibody-drug conjugate target expression in urothelial bladder cancer. Can Res. 2024;84(6_Supplement):4632\u20134632. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-4632.","journal-title":"Can Res"},{"issue":"20","key":"6003_CR17","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/jco.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, Hahn O, B\u00fcttner T, Roghmann F, et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J Clin Oncol. 2024;42(20):2446\u201355. https:\/\/doi.org\/10.1200\/jco.23.01983.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6003_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s1097-2765(00)80363-9","volume":"4","author":"K Rittinger","year":"1999","unstructured":"Rittinger K, Budman J, Xu J, Volinia S, Cantley LC, Smerdon SJ, et al. Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell. 1999;4(2):153\u201366. https:\/\/doi.org\/10.1016\/s1097-2765(00)80363-9.","journal-title":"Mol Cell"},{"issue":"1","key":"6003_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tcb.2008.10.003","volume":"19","author":"DK Morrison","year":"2009","unstructured":"Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009;19(1):16\u201323. https:\/\/doi.org\/10.1016\/j.tcb.2008.10.003.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"6003_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.drudis.2015.09.012","volume":"21","author":"Y Aghazadeh","year":"2016","unstructured":"Aghazadeh Y, Papadopoulos V. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21(2):278\u201387. https:\/\/doi.org\/10.1016\/j.drudis.2015.09.012.","journal-title":"Drug Discov Today"},{"issue":"3","key":"6003_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.yjmcc.2004.04.015","volume":"37","author":"E Wilker","year":"2004","unstructured":"Wilker E, Yaffe MB. 14-3-3 proteins\u2014a focus on cancer and human disease. J Mol Cell Cardiol. 2004;37(3):633\u201342. https:\/\/doi.org\/10.1016\/j.yjmcc.2004.04.015.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"6003_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.semcdb.2011.08.009","volume":"22","author":"AK Freeman","year":"2011","unstructured":"Freeman AK, Morrison DK. 14-3-3 proteins: diverse functions in cell proliferation and cancer progression. Semin Cell Dev Biol. 2011;22(7):681\u20137. https:\/\/doi.org\/10.1016\/j.semcdb.2011.08.009.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"6003_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/s0092-8674(00)81067-3","volume":"84","author":"AJ Muslin","year":"1996","unstructured":"Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889\u201397. https:\/\/doi.org\/10.1016\/s0092-8674(00)81067-3.","journal-title":"Cell"},{"issue":"7783","key":"6003_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41586-019-1660-y","volume":"575","author":"E Park","year":"2019","unstructured":"Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GG, et al. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature. 2019;575(7783):545\u201350. https:\/\/doi.org\/10.1038\/s41586-019-1660-y.","journal-title":"Nature"},{"key":"6003_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.632466","volume":"12","author":"XG Ye","year":"2021","unstructured":"Ye XG, Liu ZG, Wang J, Dai JM, Qiao PX, Gao PM, et al. YWHAG mutations cause childhood myoclonic epilepsy and febrile seizures: molecular sub-regional effect and mechanism. Front Genet. 2021;12: 632466. https:\/\/doi.org\/10.3389\/fgene.2021.632466.","journal-title":"Front Genet"},{"issue":"2","key":"6003_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/geno.1999.5887","volume":"60","author":"M Horie","year":"1999","unstructured":"Horie M, Suzuki M, Takahashi E, Tanigami A. Cloning, expression, and chromosomal mapping of the human 14-3-3gamma gene (YWHAG) to 7q11.23. Genomics. 1999;60(2):241\u20133. https:\/\/doi.org\/10.1006\/geno.1999.5887.","journal-title":"Genomics"},{"issue":"8","key":"6003_CR27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s00204-020-02782-7","volume":"94","author":"J Ni","year":"2020","unstructured":"Ni J, Wang J, Fu Y, Yan C, Zhu M, Jiang Y, et al. Functional genetic variants in centrosome-related genes CEP72 and YWHAG confer susceptibility to gastric cancer. Arch Toxicol. 2020;94(8):2861\u201372. https:\/\/doi.org\/10.1007\/s00204-020-02782-7.","journal-title":"Arch Toxicol"},{"issue":"31","key":"6003_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301714","volume":"10","author":"JXT Lee","year":"2023","unstructured":"Lee JXT, Tan WR, Low ZS, Lee JQ, Chua D, Yeo WDC, et al. YWHAG deficiency disrupts the EMT-associated network to induce oxidative cell death and prevent metastasis. Adv Sci. 2023;10(31): e2301714. https:\/\/doi.org\/10.1002\/advs.202301714.","journal-title":"Adv Sci"},{"issue":"7","key":"6003_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-021-03921-3","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Wang J, He Z, Chen P, Jiang X, Chen Y, et al. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Cell Death Dis. 2021;12(7):648. https:\/\/doi.org\/10.1038\/s41419-021-03921-3.","journal-title":"Cell Death Dis"},{"issue":"6 Pt 1","key":"6003_CR30","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1083\/jcb.127.6.1627","volume":"127","author":"A Weber","year":"1994","unstructured":"Weber A, Pennise CR, Babcock GG, Fowler VM. Tropomodulin caps the pointed ends of actin filaments. J Cell Biol. 1994;127(6 Pt 1):1627\u201335. https:\/\/doi.org\/10.1083\/jcb.127.6.1627.","journal-title":"J Cell Biol"},{"issue":"7","key":"6003_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/emboj.2011.48","volume":"30","author":"A Narita","year":"2011","unstructured":"Narita A, Oda T, Ma\u00e9da Y. Structural basis for the slow dynamics of the actin filament pointed end. Embo J. 2011;30(7):1230\u20137. https:\/\/doi.org\/10.1038\/emboj.2011.48.","journal-title":"Embo J"},{"issue":"3","key":"6003_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/carcin\/bgab121","volume":"43","author":"H Li","year":"2022","unstructured":"Li H, Zhao S, Chen X, Feng G, Chen Z, Fan S. MiR-145 modulates the radiosensitivity of non-small cell lung cancer cells by suppression of TMOD3. Carcinogenesis. 2022;43(3):288\u201396. https:\/\/doi.org\/10.1093\/carcin\/bgab121.","journal-title":"Carcinogenesis"},{"issue":"5","key":"6003_CR33","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3892\/or.2019.7052","volume":"41","author":"C Jin","year":"2019","unstructured":"Jin C, Chen Z, Shi W, Lian Q. Tropomodulin 3 promotes liver cancer progression by activating the MAPK\/ERK signaling pathway. Oncol Rep. 2019;41(5):3060\u20138. https:\/\/doi.org\/10.3892\/or.2019.7052.","journal-title":"Oncol Rep"},{"issue":"10","key":"6003_CR34","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/mc.23083","volume":"58","author":"H Zheng","year":"2019","unstructured":"Zheng H, Yang Y, Hong YG, Wang MC, Yuan SX, Wang ZG, et al. Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis. Mol Carcinog. 2019;58(10):1897\u2013907. https:\/\/doi.org\/10.1002\/mc.23083.","journal-title":"Mol Carcinog"},{"issue":"8","key":"6003_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537\u201349. https:\/\/doi.org\/10.1038\/nrc2694.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"6003_CR36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/cells8050426","volume":"8","author":"J Luo","year":"2019","unstructured":"Luo J, Yu F-X. GPCR-hippo signaling in cancer. Cells. 2019;8(5):426. https:\/\/doi.org\/10.3390\/cells8050426.","journal-title":"Cells"},{"issue":"1","key":"6003_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"issue":"5","key":"6003_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12282-019-00957-4","volume":"26","author":"E Hiraoka","year":"2019","unstructured":"Hiraoka E, Mimae T, Ito M, Kadoya T, Miyata Y, Ito A, et al. Breast cancer cell motility is promoted by 14-3-3\u03b3. Breast Cancer. 2019;26(5):581\u201393. https:\/\/doi.org\/10.1007\/s12282-019-00957-4.","journal-title":"Breast Cancer"},{"issue":"7 Pt A","key":"6003_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.bbamcr.2016.04.016","volume":"1863","author":"JO Yoo","year":"2016","unstructured":"Yoo JO, Kwak SY, An HJ, Bae IH, Park MJ, Han YH. miR-181b-3p promotes epithelial\u2013mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. Biochim Biophys Acta. 2016;1863(7 Pt A):1601\u201311. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.04.016.","journal-title":"Biochim Biophys Acta"},{"issue":"35","key":"6003_CR40","doi-asserted-by":"publisher","first-page":"57239","DOI":"10.18632\/oncotarget.11136","volume":"7","author":"T Joshi","year":"2016","unstructured":"Joshi T, Elias D, Stenvang J, Alves CL, Teng F, Lyng MB, et al. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget. 2016;7(35):57239\u201353. https:\/\/doi.org\/10.18632\/oncotarget.11136.","journal-title":"Oncotarget"},{"issue":"4","key":"6003_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.bbrc.2016.11.136","volume":"482","author":"P Wang","year":"2017","unstructured":"Wang P, Deng Y, Fu X. MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 2017;482(4):935\u201341. https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"6003_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2022.12719","volume":"25","author":"J Wang","year":"2022","unstructured":"Wang J, Pan X, Li J, Zhao J. TXNDC9 knockdown inhibits lung adenocarcinoma progression by targeting YWHAG. Mol Med Rep. 2022;25(6):1\u201310. https:\/\/doi.org\/10.3892\/mmr.2022.12719.","journal-title":"Mol Med Rep"},{"key":"6003_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cyto.2016.12.013","volume":"92","author":"H Wang","year":"2017","unstructured":"Wang H, Zhi H, Ma D, Li T. MiR-217 promoted the proliferation and invasion of glioblastoma by repressing YWHAG. Cytokine. 2017;92:93\u2013102. https:\/\/doi.org\/10.1016\/j.cyto.2016.12.013.","journal-title":"Cytokine"},{"issue":"8","key":"6003_CR44","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u201379. https:\/\/doi.org\/10.1016\/j.cell.2023.03.003.","journal-title":"Cell"},{"issue":"1","key":"6003_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016.","journal-title":"Eur Urol"},{"key":"6003_CR46","doi-asserted-by":"publisher","unstructured":"Bladder cancer. Nat Rev Dis Prim. 2023;9(1):59. https:\/\/doi.org\/10.1038\/s41572-023-00475-w.","DOI":"10.1038\/s41572-023-00475-w."},{"issue":"2","key":"6003_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.eururo.2011.10.011","volume":"61","author":"SF Shariat","year":"2012","unstructured":"Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol. 2012;61(2):237\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.011.","journal-title":"Eur Urol"},{"key":"6003_CR48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.canlet.2018.10.015","volume":"442","author":"S Wen","year":"2019","unstructured":"Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin \u03b23-p38 MAPK signalling. Cancer Lett. 2019;442:320\u201332. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.015.","journal-title":"Cancer Lett"},{"issue":"4","key":"6003_CR49","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/0008-5472.Can-20-0049","volume":"81","author":"S Wu","year":"2021","unstructured":"Wu S, Chen M, Huang J, Zhang F, Lv Z, Jia Y, et al. ORAI2 promotes gastric cancer tumorigenicity and metastasis through PI3K\/Akt signaling and MAPK-dependent focal adhesion disassembly. Cancer Res. 2021;81(4):986\u20131000. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-0049.","journal-title":"Cancer Res"},{"issue":"7","key":"6003_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166400","volume":"1868","author":"R Rakesh","year":"2022","unstructured":"Rakesh R, PriyaDharshini LC, Sakthivel KM, Rasmi RR. Role and regulation of autophagy in cancer. Biochim Biophys Acta Mol Basis Dis. 2022;1868(7): 166400. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166400.","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-06003-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T06:01:56Z","timestamp":1735624916000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-06003-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6003"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-06003-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Peking University First Hospital (Ethics ID: 2024096-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1159"}}